Abstract:Background: For advanced or metastatic lung cancer patients (pts) in the absence of actionable genetic alterations, whose disease progressed after chemotherapy, the effective treatment options are limited. Recently, PD-1/PD-L1 inhibitors have demonstrated improved survival in advanced lung cancer. However, sufficient evidence is still lacking in Chinese lung cancer pts. Methods: Twenty lung cancer pts including 12 adenocarcinomas and 5 squamous cell carcinomas who received anti-PD-1/PD-L1 treatments as first- to fourth-line therapy were retrospectively reviewed. The majority of the pts were stage IV (17 pts). PD-L1 expression was analyzed by immunohistochemical staining. Genomic alterations were detected by using a next-generation sequencing (NGS) assay targeting 450 cancer genes. Tumor mutational burden (TMB) and microsatellite instability (MSI) status were acquired by NGS algorithm. Results: The median age of the 20 pts was 57 years (range: 36-69) and male vs. female was 3. The median time from date of diagnosis to the date of the first anti-PD-1/PD-L1 treatment was 9.5 months (range: 1-69 months). The overall response rate was 89%, including 8 partial response (PR), 9 stable disease (SD) and 2 progressive disease (PD), and the median PFS (mPFS) was not reached (NR) (range: 0.5-NR). Seven pts had one or more targetable oncogenic mutations including EGFR L858R (2) and amplification, PIK3CA (1), BRAF, ERBB2, PTEN, and ROS1 fusion. The median TMB value of the 20 pts was 11 muts/Mb (range: 2.4-38 muts/Mb). 45% of the pts had TMB greater than 20 muts/Mb, and 60% had TMB greater than 10 muts/Mb. Among the 9 pts who had the TMB greater than 20 muts/Mb, 5 pts achieved PR, 4 achieved SD, mPFS was not reached. Also, 5 pts including 2 PR and 3 SD were identified as MSI-high. In the PD-L1 positive subgroup (N=11), 5 pts achieved PR, 5 achieved SD and 1 had a PD. Furthermore, we found 5 pts with NFE2L2 mutations including 2 adenocarcinomas and 3 squamous cell carcinomas, associated with high TMB values (>20 muts/Mb) and PD-L1 positivity; all 5 pts had response to anti-PD-1/PD-L1 treatment, which include 3 PR and 2 SD with mPFS not reached (range: 6-NR). Conclusion: Our preliminary results based on a small number of pts showed a significant association between high TMB values and response of immune checkpoint inhibitors in Chinese lung cancer pts, and a strong correlation between high TMB values and high PD-L1 expression. We also reported that NFE2L2 mutation was tightly associated with high TMB value (P=0.011) and PD-L1 positivity (P=0.038), which may serve as a new predictive biomarker for advanced or metastatic lung cancer pts receiving anti-PD-1/PD-L1 treatments. Further larger cohort study is warranted. Citation Format: Jing Hu, Bixun Li, Bing Zou, Senming Wang, Ye Qiu, Maolin Yan, Zhiming Zeng, Han Yang, Yan Guan, Lei Zhang, Wei Chen, Yuan Zhang, Lei Mei, Xiaowei Dong, Ming Yao, Kai Wang. Associations of genomic alteration, tumor mutational burden with PD-L1 expression and response to immune checkpoint inhibitors in Chinese lung patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 620.

Programmed Cell Death-1 (Pd-L1) Expression and Fibroblast Growth Factor Receptor 1 (fgfr1) Amplification in Chinese Stage Iii/Iv Lung Squamous Lung Carcinoma (Sqc).

Programmed Cell Death‐ligand 1 (PD‐L1) Expression and Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification in Stage III/IV Lung Squamous Cell Carcinoma (SQC)

Current Status of PD-(L)1 Inhibitor Usage in Advanced or Metastatic Non-Small Cell Lung Cancer: A National Survey of Oncologists in China.

Abstract 620: Associations of Genomic Alteration, Tumor Mutational Burden with PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Chinese Lung Patients

FGFR1 Amplification and EGFR Mutation in Chinese Squamous Cell Lung Cancer.

FGFR Genes Mutation is an Independent Prognostic Factor and Associated with Lymph Node Metastasis in Squamous Non-Small Cell Lung Cancer

Abstract 2635: Differential Prognostic Implications of Programmed Death-Ligand 1 Expression on Tumor Cells and Tumor-Infiltrating Immune Cells in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Treated with Preoperative Chemoradiotherapy

FGF19 Genetic Amplification As a Potential Therapeutic Target in Lung Squamous Cell Carcinomas.

MA 13.02 Comprehensive Genetic Analysis Related to PD-L1 Expression in Early-stage Lung Squamous Cell Carcinoma

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

Association of Frequent Amplification of Chromosome 11q13 in Esophageal Squamous Cell Cancer with Clinical Benefit to Immune Check Point Blockade.

Comprehensive Investigation of Clinicopathologic Features, Oncogenic Driver Mutations and Immunohistochemical Markers in Peripheral Lung Squamous Cell Carcinoma.

Prevalence of Gene Amplifications of Sox-2, C-Met, and Fgfr1 in Asian Patients with Esophageal Squamous Cell Carcinoma.

The Role of FGFR1 Gene Amplification As a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published Data.

Prognostic significance of PD-L1 expression and 18 F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.

Expression of P63 and CK5/6 in Early-Stage Lung Squamous Cell Carcinoma is Not Only an Early Diagnostic Indicator but Also Correlates with a Good Prognosis

PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer

P1.03-06 Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer

PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer